NEW YORK, NY / ACCESS Newswire / May 5, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=146991&wire=1 or contact Joseph E. Levi, Esq.

FDEV is a passively managed ETF that leverages a sophisticated, factor-driven strategy applied to the developed world equities. At this point, FDEV has a Japan-heavy portfolio with a low P/E and financials as the key sector. Its overlap with IDEV is close to 100%. Unfortunately, its long-term returns have been mostly a disappointment, as it has trailed SCHF and IDEV, as well as a few peers.

Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q1 2025 Earnings Conference Call May 5, 2025 8:00 AM ET Company Participants Darren Opland - Director, Corporate Communications Herriot Tabuteau - CEO Nick Pizzie - CFO Ari Maizel - Chief Commercial Officer Mark Jacobson - COO Hunter Murdock - General Counsel Conference Call Participants Leonid Timashev - RBC Capital Markets Marc Goodman - Leerink Partners Andrew Tsai - Jefferies Ash Verma - UBS Ram Selvaraju - H.C. Wainwright Charles Duncan - Cantor Fitzgerald David Amsellem - Piper Sandler David Hoang - Deutsche Bank Joon Lee - Truist Securities Cerena Chen - Wells Fargo Jason …

NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Viatris, Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The U.S. Food and Drug Administration (FDA) has approved Teva Pharmaceutical Industries Ltd. TEVA and Alvotech's ALVO Selarsdi (ustekinumab-aekn) injection as interchangeable with the reference biologic Johnson & Johnson's JNJ Stelara (ustekinumab).

Twist Bioscience Corporation (NASDAQ:TWST ) Q2 2025 Earnings Conference Call April 5, 2025 8:00 AM ET Company Participants Angela Bitting - Senior Vice President of Corporate Affairs Emily Leproust - Chief Executive Officer Patrick Finn - President and Chief Operating Officer Adam Laponis - Chief Financial Officer Conference Call Participants Luke Sergott - Barclays Matthew Sykes - Goldman Sachs Subbu Nambi - Guggenheim Securities Doug Schenkel - Wolfe Research Vijay Kumar - Evercore ISI Matt Larew - William Blair Puneet Souda - Leerink Partners Sung-Ji Nam - Scotiabank Thomas Peterson - Baird Brendan Smith - TD Cowen Operator Good day. …

NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Open Lending Corporation. (“Open Lending” or the “Company”) (NASDAQ: LPRO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

BG's Q1 results are anticipated to reflect weak year-over-year performances in its segments and the impacts of the divestiture of the Sugar and Bioenergy segment.

BioNTech SE (NASDAQ:BNTX ) Q1 2025 Earnings Conference Call May 5, 2025 8:00 AM ET Company Participants Michael Horowicz - Director, Investor Relations Ugur Sahin - Co-Founder & Chief Executive Officer Özlem Türeci - Co-Founder & Chief Medical Officer Jens Holstein - Chief Financial Officer Ryan Richardson - Chief Strategy Officer Conference Call Participants Tazeen Ahmad - Bank of America Akash Tewari - Jefferies Daina Graybosch - Leerink Partners Cory Kasimov - Evercore Terence Flynn - Morgan Stanley Jessica Fye - JPMorgan Evan Seigerman - BMO Capital Markets Yaron Werber - TD Cowen Mohit Bansal - Wells Fargo Harry Gillis …

The conglomerate said the legendary "Oracle of Omaha" will remain as Berkshire's chairman.

Shares of Berkshire Hathaway Inc (NYSE:BRK.A) fell 4.6% on Monday morning after the company announced that Greg Abel will take over as CEO at the start of next year, succeeding Warren Buffett after more than six decades at the helm. The leadership transition was approved unanimously by Berkshire's board following Buffett's weekend announcement to shareholders.

GSK's stock price has significantly outperformed the healthcare sector this year, supported by its healthy Q1 2025 numbers. Both turnover and EPS growth exceeded expectations, and the company's guidance indicates that the stock's forward P/E is competitive too. Additionally, GSK's medium-to-long-term financial prospects look good too, based on the company's latest outlook, which also works in the stock's favour.

Lemonade, an AI-driven property/casualty insurer, offers renters, homeowners, auto, pet, and term life insurance, aiming for 30%+ growth in revenues and in-force premiums. Despite recent stock price declines and analyst skepticism, Lemonade's AI and automation focus position it to improve profitability and cash flow, making it a contrarian buy. Lemonade's success hinges on its auto insurance market entry, leveraging telematics and cross-selling to younger, tech-savvy consumers, with significant growth potential.

Mettler-Toledo International's Q1 results reflect growth in the Laboratory business, a decline in Industrial, and continued weakness in the Food Retail segment.

Despite the current stock market volatility, the telecom sector has emerged as a resilient industry.

Ahead of its upcoming May 6 earnings report, and amidst Lucid (NASDAQ: LCID) stock's May 5 6.52% early session plunge to $2.38, Cantor Fitzgerald's Andres Sheppard elected to revise their price target for the beleaguered electric vehicle (EV) maker.

While the top- and bottom-line numbers for ON Semiconductor Corp. (ON) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

"There's a sense of caution" heading into Hims & Hers (HIMS) earnings, says Caroline Woods. The telehealth company is up over 65% so far in 2025 but has fallen more than 40% off its February highs.

NEW YORK, NY / ACCESS Newswire / May 5, 2025 / If you suffered a loss on your Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/maravai-lifesciences-holdings-inc-lawsuit-submission-form?prid=146986&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / May 5, 2025 / If you suffered a loss on your TFI International Inc. (NYSE:TFII) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/tfi-international-inc-lawsuit-submission-form?prid=146983&wire=1 or contact Joseph E. Levi, Esq.